Chronic rejection in kidney transplants: An in-depth review

Nephron

Volumn 83, Issue 1, 1999, Pages 13-24

  Jindal, Rahul M ^b   Hariharan, Sundaram ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ATROPHY; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; ANTIBODIES; CHRONIC DISEASE; CONTINENTAL POPULATION GROUPS; DISEASE MODELS, ANIMAL; FISH OILS; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; RATS; SEX FACTORS;

EID: 0037982675     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045468     Document Type: Review

References (74)

1. Morris PJ: Factors influencing outcome in cadaveric renal transplantation. Br J Surg 1994; 81:635.
2. Gjertson DW: Survival trends in long-term first cadaver-donor kidney transplants; in Terasaki PI, Cecka JM (eds): Clinical Transplants 1990. Los Angeles, UCLA Tissue Typing Laboratory, 1991, p 225.
3. Woodle ES, Thistlethwaite JR, Gordon JR, et al: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 1996;62:594.
4. Hume DH, Merrill JP, Miller BF, Thorn GW: Experience with renal homotransplantation in the human: Report of nine cases. J Clin Invest 1995;34:327.
5. Solez K, Axelsen RA, Benediktsson H, et al: International standardization of criteria for the histological diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993;44: 411.
6. Paul LC, Hayry P, Foegh M, et al: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the fourth Alexis Carrel conference on chronic rejection and accelerated arteriosclerosis in transplanted organs. Transplant Proc 1993;25:2022.
7. Sumrani N, Cacciarelli TV, Georgi B, et al: Contribution of acute rejection to renal allograft loss from chronic rejection. Transplant Proc 1993;25:2259.
8. Demetris AJ, Zerbe T, Banner B: Morphology of solid organ allograft arteriopathy: Identification of proliferating cell populations. Transplant Proc 1989;21:3667.
9. Knight RJ, Kerman RH, Welsh M, et al: Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy. Transplantation 1991;51:355.
10. McDonald AS, Belitsky P, Bitter-Suermann H, Cohen AD, Croker J, MacSween M: Long-term follow-up of cyclosporine treated renal allograft recipients. Transplant Proc 1988;20:1239.
11. Rao KV, Rose J: Incidence, histological patterns, and clinical outcome of rejection episodes occurring in the late post-transplant period. Transplantation 1985;40:631.
12. Kirkman RL, Strom TB, Weir MR, Tilney NL: Late mortality and morbidity in recipients of long-term allografts. Transplantation 1982;34: 347.
13. Almond PS, Matas A, Gillingham K, et al: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752.
14. Merion RM, White DJG, Thiru S, Evans DB, Calne RY: Cyclosporine: Five years experience in cadaveric renal transplantation. N Engl J Med 1984;310:148.
15. Paul LC: Chronic renal transplant loss. Kidney Int 1995;47:1491.
16. Lorber MI, Flechner SM, Van Buren CT, et al: Cyclosporine, azathioprine, and prednisone as treatment for cyclosporine-induced nephrotoxicity in renal transplant recipients. Transplant Proc 1985;17:282.
17. Hayry P, Isoniemi H, Yilmaz S, et al: Chronic allograft rejection. Immunol Rev 1993;134:33.
18. Valente JF, Hariharan S, Peddi VR, et al: Causes of renal allograft loss in black vs. white transplant recipients in the cyclosporine era. Clin Transplant 1997;11:231.
19. Schroeder TJ, Hariharan S, First MR: Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant sub-populations. Transplant Proc 1995; 27:837.
20. Neugarten J, Srinivas T, Tellis V, Silbiger S, Greenstein S: The effect of donor gender on renal allograft survival. J Am Soc Nephrol 1996;7:318.
21. Nyengaard JR, Bendtsen TF: Glomerular number and size in relation to age, kidney weight and body surface in normal man. Anat Rec 1992;232:194.
22. Terasaki PI, Gjertson DW, Cecka JM, Takemoto S: Fit and match hypothesis for kidney transplantation. Transplantation 1996;62:441.
23. Simamura T, Morrison AB: A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 1975;79:95.
24. Salahudeen AK, Hostetter TH, Raatz SK, Risenberg ME: Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int 1992;41:183.
25. Markel MS, Sumrani N, DiBenedetto A, Friedman EA: Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis 1993; 22:233.
26. Kasiske BL, O'Donnell MP, Keane WP: The Zucker rat model of obesity, insulin resistance, hyperlipidemia and renal injury. Hypertension, 1992;19(suppl):1110.
27. Dimeny E, Fellstrom B, Larsson E. Tufreson G, Lithell H: Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant 1993;7:482.
28. Meister BM, Wenke K, Thiery J, et al: Simastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993;25:2077.
29. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al: Hypercholesterolemia: A significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994;9:1103.
30. Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV: The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991;17: 700.
31. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561.
32. Richardson WP, Colvin RB, Cheeseman SK, et al: Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981;305:57.
33. Herrera GA, Alexander RW, Cooley CF, et al: Cytomegalovirus glomerulopathy: A controversial lesion. Kidney Int 1986;29:725.
34. Tullius SG, Tilney NL: Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation 1995;59:313.
35. Heemann US, Tullius SG, Schmid C, Philipp T, Tilney NL: Infection-associatcd cellular activation accelerates chronic renal allograft rejection in rats. Transplant Int 1996;9:137.
36. Hariharan S, Alexander JW, Schroeder TJ, First MR: Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival. Clin Transplant 1996; 10:538.
37. Tesi RJ, Henry ML, Elkammas EA, Ferguson RM: Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993;7:345.
38. Cecka JM: The UNOS scientific renal transplant registry; in Terasaki PI, Cecka JM (eds): Clinical Transplants 1996. Los Angeles, UCLA Tissue Typing Laboratory, 1997, p 1.
39. Cosio FG, Pelletier RP, Falkenhain MF, et al: Impact of acute rejection and early allograft function on renal allograft survival. Transplantation 1997;63:1611.
40. Tejani A, Cortes L, Stablein D: Clinical correlates of chronic rejection in pediatric renal transplantation. Transplantation 1996;61: 1054.
41. Ingulli E, Tejani A: Racial differences in the incidence and outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991;5:393.
42. Wrenshall LE, Matas AJ, Canafax DM, et al: An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone. Transplantation 1990;50:233.
43. Kiley DJ, Lam CS, Pollak R: A study of compliance following kidney transplantation. Transplantation 1993;55:51.
44. Rush DN, Jeffery JR, Grough S: Sequential protocol biopsies in renal transplant patients. Transplantation 1995;59:511.
45. Najarian JS, Simmons SL, Conti RM, et al: Seven years experience with antilymphoblasts in patients with renal allografts from cadaver donors. Ann Surg 1976;184:352.
46. Szczech LA, Berlon JA, Aradhye S, Grossman RA, Feldman HI: Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta analysis. J Am Soc Nephrol 1997;8:1771.
47. Hariharan S, Alexander JW, Schroeder TJ, First MR: Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Clin Transplant 1996;10:186.
48. Shokes DA, Parfrey NA, Halloran PF: Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation 1990;49:210.
49. Sharma VK, Bologa RM, Xu GP, et al: Intragraft TGF-β, mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996;49:1297.
50. Gould VE, Martinez-Lacabe V, Viratanen I, Sahlin KM, Schwartz MM: Differential distribution of tenascin and cellular fibronectins in acute and chronic renal allograft rejection. Lab Invest 1992;67:71.
51. Li B, Sehajpal PK, Khanna A, et al: Differential regulation of transforming growth factor-β and interlenken-2 genes in human T cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991;174:1259.
52. Gibbons GH, Pratl RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456.
53. Fellstrom B, Klareskog L, Heldon CH, et al: Platelet derived growth factor receptors in the kidney-upregulated expression in inflammation. Kidney Int 1989;36:1099.
54. Dallman MJ: The cytokine network and regulation of the immune response to organ transplants. Transplant Rev 1992;6:209.
55. Starzl TE, Demetris AJ: Transplantation milestones: Viewed with one and two-way paradigms of tolerance. JAMA 1995;273:876.
56. Rolles K, Burroughs AK, Davidson BR, et al: Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet 1994; 343:263.
57. Rao AS, Fontes P, Dodson F, et al: Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc 1996;28:2959.
58. Jonsson JR, Hogan PG, Thomas R, et al: Peripheral blood chimerism following human liver transplantation. Hepatology 1997;25:1233.
59. Reinsmoen NL, Jackson A, McSherry C, et al: Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogenic microchimerism in lung, kidney, and liver transplant recipients. Transplantation 1995; 60:1546.
60. Elwood ET, Larsen CP, Maurer DH, et al: Microchimerism and rejection in clinical transplantation. Lancet 1997;349:1358.
61. Jindal RM, Sahota A: The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Postgrad Med J 1997;73:146.
62. Azuma H, Tilney NL: Chronic graft rejection. Curr Opin Immunol 1994;6:770.
63. Hayry P, Mennander A, Raisanen-Sokolowski A, et al: Pathophysiology of vascular wall changes in chronic allograft rejection. Transplant Rev 1993;7:1.
64. Mennander A, Tiisala S, Halttunen J, et al: Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis. Arterioscler Thromb 1991;11:671.
65. Diamond JR, Tilney NL, Frye J, et al: Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992;54:710.
66. Beckingham IJ, O'Rourke JS, Subington SR, Hinwood M, Bishop MC, Rigg KM: Impact of cyclosporine on the incidence and prevalence of chronic rejection in renal transplants. Ann R Coll Surg 1997;79:138.
67. Thorogood J, Van Houwelingen HC, Van Rood JJ, et al: Long-term results of kidney transplantation in Eurotransplant; in Paul LC, Solez K (eds): Organ Transplantation: Long-Term Results. New York, Dekker, 1992, p 33.
68. Jordan MI, Shapiro R, Vivas CA, et al: FK506 'rescue' for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994;57:860.
69. The Tri-Continental Mycophenolate Mofetil Renal Transplant Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996;61:1029.
70. Cao W, Mohasesi P, Shorthoure R, et al: Effect of rapamycin on growth factor stimulated vascular smooth muscle cell DNA synthesis. Transplantation 1995;76:412.
71. Xiao F, Chong A, Shen J, et al: Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995;60:1065.
72. Jindal RM, Sidner RA, Milgrom ML: Posttransplant diabetes mellitus: The role of immunosuppression. Drug Safety 1997;16:242.
73. Sweny P, Wheeler DC, Lui SF, et al: Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 1989;4: 1070.
74. Kobashigawa JA, Katznelson S, Laks H, et al: Effect of pravastatin on outcomes after cadaveric transplantation. N Engl J Med 1995;333: 621.